Omalizumab for asthma
Omalizumab for asthma is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
"Omalizumab for Asthma." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma.
Omalizumab for asthma. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma. Accessed March 28, 2023.
Omalizumab for asthma. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma
Omalizumab for Asthma [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 28]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Omalizumab for asthma ID - 455460 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -